# ADELA (NCT06382948)

> Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06382948
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: MedSIR
- Conditions: Advanced Breast Cancer; ER-positive Breast Cancer; HER2-negative Breast Cancer; ESR1 Gene Mutation
- Interventions: Everolimus; Elacestrant; Placebo; Auxiliary Medicinal Product - Dexamethasone; Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
- Enrollment: 300
- Primary outcome: To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).

## Commentary we found

- YouTube: 9
- Podcasts: 6
- X threads: 2

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=adela-nct06382948

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06382948", "email": "<work email>"}; the inbox owner confirms by the emailed link.